Related Experiment Video
Updated: Dec 28, 2025
08:45
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
1.3K
Anticoagulation in the cirrhotic patient
Laura Turco1,2, Emmanuelle de Raucourt3, Dominique-Charles Valla4
1Department of Gastroenterology, University of Modena & Reggio Emilia and Azienda Ospedaliero-Universitaria di Modena, Italy.
JHEP Reports : Innovation in Hepatology
|February 11, 2020
Summary
Patients with liver cirrhosis face higher risks of blood clots than bleeding. Anticoagulation therapy, including new oral anticoagulants, improves outcomes and survival in these patients.
Area of Science:
- Hepatology
- Hematology
- Clinical Medicine
Background:
- Historically, liver cirrhosis was associated with bleeding risks.
- Compensated cirrhosis exhibits normal coagulation, but decompensation can alter this balance.
- Current understanding indicates a shift towards thrombotic risks in advanced liver cirrhosis.
Purpose of the Study:
- To review the evolving understanding of coagulation in liver cirrhosis.
- To evaluate the role and safety of anticoagulation in liver cirrhosis patients.
- To assess the potential of novel oral anticoagulants in this population.
Main Methods:
- Literature review of studies on coagulation and anticoagulation in liver cirrhosis.
- Analysis of clinical outcomes associated with anticoagulation therapy.
- Examination of preliminary data on novel oral anticoagulants.
Main Results:
- Patients with liver cirrhosis are now recognized to have a higher risk of thrombosis.
- Anticoagulation, both therapeutic and prophylactic, is linked to reduced decompensation and improved survival.
- Established anticoagulants include low molecular weight heparins and vitamin K antagonists.
Conclusions:
- Anticoagulation is beneficial in managing thrombotic risks in liver cirrhosis.
- Novel non-vitamin K antagonist oral anticoagulants show promise for safe use in liver cirrhosis.
- Further research is warranted to confirm the safety and efficacy of novel anticoagulants.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:29Venous Thrombosis III: Interprofessional Care
228
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
168
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
168
01:30Venous Thrombosis IV: Nursing Management
157
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157
01:28Esophageal Varices-II: Clinical Features and Management
314
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
314